Coronavirus

Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2022 and Provides Business Update

Retrieved on: 
Monday, August 15, 2022
GLOBE, Cirrhosis, SEC, Clinical trial, Cancer, Research, USAN, Marketing, Patient, Fatty liver disease, Animal, Food, Disease, Liver, Safety, Esophageal varices, Ethics, Chronic liver disease, Inflammation, Food and Drug Administration Amendments Act of 2007, Private Securities Litigation Reform Act, International Studies of Infarct Survival, Liver transplantation, Fibrosis, Immunotherapy, GALT, Conference, Galectin, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Efficacy, NASH, Therapy, COVID-19, Program, Coronavirus, Kidney, Chemistry, Lung, Head, Lists of diseases, FDA, Non-alcoholic fatty liver disease, Obesity, Liver disease, IND, OOD, Hope, Company, NASDAQ, Drug discovery, Heart, Pharmaceutical industry

NORCROSS, Ga., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended June 30, 2022.

Key Points: 
  • NORCROSS, Ga., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended June 30, 2022.
  • Joel Lewis, Chief Executive Officer and President, stated: Our team made significant progress on a number of fronts this quarter.
  • His unwavering commitment clearly has provided the resources necessary for the successful completion of our global pivotal clinical trial.
  • Galectin Therapeutics and its associated logo is a registered trademark of Galectin Therapeutics Inc. Belapectin is the USAN assigned name for Galectin Therapeutics galectin-3 inhibitor belapectin (GR-MD-02).

UPHEALTH ANNOUNCES $67.5 MILLION CONVERTIBLE DEBT FINANCING

Retrieved on: 
Monday, August 15, 2022
Securities Act of 1933, NYSE, A.D. Bedell Wholesale Co., Inc. v. Philip Morris Inc., CFO, Sale, SEC Rule 144A, Perception, The Company, SOFR, Language, Government, Patient, COVID-19, Company, Twitter, Health, UPH, Coronavirus, LinkedIn, Note, Borrowing base, Security (finance)

DELRAY BEACH, Fla., Aug. 15, 2022 /PRNewswire/ -- UpHealth, Inc. ("UpHealth" or the "Company") (NYSE: UPH), a global digital health company delivering technology platforms, infrastructure, and services to modernize care delivery and health management, today announced the sale of $67.5 million in aggregate principal amount of a new series of variable rate convertible senior secured notes due December 15, 2025 (the "2025 Notes") in a private placement transaction, raising approximately $22.5 million in gross cash proceeds after paying for a repurchase of $45.0 million of its 6.25% convertible senior notes due 2026. The 2025 Notes are convertible into shares of UpHealth common stock at a conversion price of $1.75 per share, which represents a 101% premium over the most recent closing price of UpHealth's common stock.

Key Points: 
  • The 2025 Notes are convertible into shares of UpHealth common stock at a conversion price of $1.75 per share, which represents a 101% premium over the most recent closing price of UpHealth's common stock.
  • UpHealth will settle conversions solely in shares of its common stock, except for payments of cash in lieu of fractional shares.
  • For more information, please visit https://uphealthinc.com and follow us at @UpHealthInc on Twitter and UpHealth Inc on LinkedIn.
  • Such forward-looking statements include, but are not limited to, statements regarding payments pursuant to the terms of UpHealth's debt obligations and the conversion or maturity of such debt.

The Worldwide Video Games Industry is Expected to Reach $294.3 Billion in 2026 - ResearchAndMarkets.com

Retrieved on: 
Monday, August 15, 2022
Electronic Games, Entertainment, Movement, Nintendo, Growth, Electronic art, Microsoft, Video, Console, COVID-19, Apple Inc., Sony, CAGR, Tencent, Coronavirus, US, Internet, Video game, Animal

The global video game market is forecasted to reach US$294.35 billion in 2026, experiencing growth at a CAGR of 8.53% during the period spanning from 2022 to 2026.

Key Points: 
  • The global video game market is forecasted to reach US$294.35 billion in 2026, experiencing growth at a CAGR of 8.53% during the period spanning from 2022 to 2026.
  • However, the market growth is expected to be restrained by piracy protection issues, cyber security issues and health issues.
  • The global video game market by device can be segmented as follows: mobile, console and personal computer (PC).
  • In 2021, the dominant share of global video game was being held by mobile, followed by console.

World Consumer Foodservice Market Report 2022: Buzz Topics, Emerging Geographies, Categories and Trends - ResearchAndMarkets.com

Retrieved on: 
Monday, August 15, 2022
Retail, Restaurant, Bar, Food, Beverage, Consumer, Environment, Industry, Use, COVID-19, Foodservice, Coronavirus

The "World Market for Consumer Foodservice" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "World Market for Consumer Foodservice" report has been added to ResearchAndMarkets.com's offering.
  • The World Market for Consumer Foodservice global briefing offers an insight into to the size and shape of the Consumer Foodservice market, highlights buzz topics, emerging geographies, categories and trends as well as pressing industry issues and white spaces.
  • The Coronavirus (COVID-19) pandemic has devastated the global foodservice industry in the short term, while radically accelerating existing trends.
  • Surging investment in delivery and online ordering has combined with massive new demand for prepared meals consumed at home.

Aerie Pharmaceuticals Announces New Employee Inducement Grant

Retrieved on: 
Monday, August 15, 2022
Pharmaceutical, Health, Optical, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, U.S. Securities and Exchange Commission, Duane syndrome, NDA, Industry, Forward-looking statement, Food, Aerie Pharmaceuticals, Private Securities Litigation Reform Act, SEC, DME, Ocular hypertension, Security (finance), Netarsudil, Eye, Patient, COVID-19, Company, Diabetic retinopathy, Nature, NASDAQ, Coronavirus, Conjunctivitis, Glaucoma, Medication, Employment, Aerie, IOP, New Drug Application, Retina, Pharmaceutical industry

In clinical trials of Rhopressa, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage.

Key Points: 
  • In clinical trials of Rhopressa, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage.
  • In clinical trials of Rocklatan, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage.
  • More information on Aerie Pharmaceuticals is available at www.aeriepharma.com .
  • Any forward-looking statements that we make in this press release speak only as of the date of this press release.

Liberty Gold Receives Final US$6 Million Payment for the Sale of Halilağa Copper-Gold Deposit, Turkey

Retrieved on: 
Monday, August 15, 2022
U.S. Securities and Exchange Commission, Disclosure, SEDAR, Industry, CEO, GLOBE, Phrase, Mineral, Radio masts and towers, TSX, SEC, National instrument, Sale, Mineral resource estimation, Great Basin, Hyperaccumulators table – 2 : Nickel, Silver, COVID-19, Company, Liberty, Goldstrike mine, Technical report, Mining, LGD, Risk, Coronavirus, Intention, TVT, News, Gold, US, Cengiz Holding, Time, Kayyali, OTCQX, Risk management, Copper, Cryptocurrency, Black pine

VANCOUVER, British Columbia, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Liberty Gold Corp. (TSX:LGD; OTCQX:LGDTF) ("Liberty Gold" or the Company) is pleased to announce the receipt of the final US$6.0 million cash payment as final consideration for the sale of its 40% interest in the Halilaa copper-gold porphyry deposit (Halilaa), located in Biga Province, northwest Turkey to Cengiz Holdings A.. (the Halilaa Sale Agreement).

Key Points: 
  • VANCOUVER, British Columbia, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Liberty Gold Corp. (TSX:LGD; OTCQX:LGDTF) ("Liberty Gold" or the Company) is pleased to announce the receipt of the final US$6.0 million cash payment as final consideration for the sale of its 40% interest in the Halilaa copper-gold porphyry deposit (Halilaa), located in Biga Province, northwest Turkey to Cengiz Holdings A.. (the Halilaa Sale Agreement).
  • Liberty Gold has received US$22.0 million to-date from the sale of Halilaa.
  • Cal Everett, CEO of Liberty Gold stated, We are pleased to the report receipt of the final payment in this important transaction.
  • 1 See press release on May18, 2021 , Liberty Gold Files Technical Report on SEDAR for the Resource Estimate at TV Tower, Western Turkey

Liberty Gold Reports Q2 2022 Financial and Operating Results

Retrieved on: 
Friday, August 12, 2022
U.S. Securities and Exchange Commission, PEA, Disclosure, Industry, Phrase, Mineral, SEC, COVID-19, Company, Liberty, Goldstrike mine, Inference, Mining, Pea, Risk, Coronavirus, Intention, News, Gold, Time, Great Basin, Risk management, Cryptocurrency, Renewable energy

Liberty Gold is focused on exploring for and developing open pit oxide deposits in the Great Basin of the United States, home to large-scale gold projects that are ideal for open-pit mining.

Key Points: 
  • Liberty Gold is focused on exploring for and developing open pit oxide deposits in the Great Basin of the United States, home to large-scale gold projects that are ideal for open-pit mining.
  • We know the Great Basin and are driven to discover and advance big gold deposits that can be mined profitably in open-pit scenarios.
  • Many assumptions are based on factors and events that are not within the control of Liberty Gold and there is no assurance they will prove to be correct.
  • 2 See press release dated June 27, 2022
    3 See press release dated March 25, 2022
    4 See press release dated January 18, 2022, February 23, 2022, and April 12, 2022
    5 See press release dated August 9, 2022

Daily Journal Corporation Announces Financial Results for the Nine Months ended June 30, 2022

Retrieved on: 
Friday, August 12, 2022
U.S. Securities and Exchange Commission, SECURE Act of 2019, Omicron, GLOBE, Securities Exchange Act of 1934, Daily Journal Corporation, Security (finance), Information services, Income, Company, Case management, Tax, NASDAQ, Intention, Tradition, Maintenance, Securities Act of 1933, Cryptocurrency, Life insurance, Coronavirus, Delta, Journal

LOS ANGELES, Aug. 12, 2022 (GLOBE NEWSWIRE) -- During the nine months ended June 30, 2022, Daily Journal Corporation (NASDAQ:DJCO) had consolidated revenues of $34,797,000 as compared with $37,952,000 in the prior year period.

Key Points: 
  • LOS ANGELES, Aug. 12, 2022 (GLOBE NEWSWIRE) -- During the nine months ended June 30, 2022, Daily Journal Corporation (NASDAQ:DJCO) had consolidated revenues of $34,797,000 as compared with $37,952,000 in the prior year period.
  • During the nine months ended June 30, 2022, consolidated pretax loss was $40,532,000, as compared to pretax income of $154,434,000 in the prior fiscal year period.
  • The shares used in the calculation were 1,380,542 and 1,380,746 for the nine months ended June 30, 2022 and 2021 respectively.
  • Daily Journal Corporation publishes newspapers and web sites covering California and Arizona, and produces several specialized information services.

Enochian Biosciences Inc. Shareholder Notice: Robbins LLP Reminds Investors of Lead Plaintiff Deadline in Class Action Against Enochian Biosciences Inc. (ENOB)

Retrieved on: 
Friday, August 12, 2022
Steps, HIV, Technology, Hindenburg Research, Securities Exchange Act of 1934, Cancer, Coronavirus, Theft, U.S. Department of Justice Office of Legislative Affairs, Felony, Company, U.S. Department of Defense Strategy for Operating in Cyberspace, Fraud, Hindenburg, NASDAQ, News, Science, Hepatitis B virus, China Biologic Products, ENOB, Justice, Complaint, Person, Crime, Enochian

If you would like more information about Enochian Biosciences Inc.'s misconduct, click here .

Key Points: 
  • If you would like more information about Enochian Biosciences Inc.'s misconduct, click here .
  • On May 25, 2022, the U.S. Department of Justice announced that Gumrukcu had been arrested and charged in a murder-for-hire conspiracy.
  • On this news, the price of Enochian's stock fell almost 37%, to close at $3.70 per share on May 25, 2022.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Increased health care use among patients after COVID-19

Retrieved on: 
Friday, August 12, 2022
Ear, Health, Health promotion, Vaccine Safety Datalink, Health education, Population, Kaiser Permanente Bernard J. Tyson School of Medicine, COVID, Center, District, Caregiver, Department, Patient, CDC, Doctor of Philosophy, Epidemic Intelligence Service, COVID-19, Infection, Evaluation, JAMA Network Open, Coronavirus, Pulmonary embolism, Nose, Marshfield Clinic, Korea Disease Control and Prevention Agency, Denver Health Medical Center, Physician, Deep vein thrombosis, Sex, Pharmaceutical industry, Animal, Kaiser Permanente

PASADENA, Calif., Aug. 12, 2022 /PRNewswire/ -- A study led by Kaiser Permanente in Southern California of patients from 8 health care organizations across the United States showed that COVID-19 was associated with a 4% increase in use of health care services over the 6 months after initial infection. The study was published August 12, 2022 in JAMA Network Open.

Key Points: 
  • PASADENA, Calif., Aug. 12, 2022 /PRNewswire/ -- A study led by Kaiser Permanente in Southern California of patients from 8 health care organizations across the United States showed that COVID-19 was associated with a 4% increase in use of health care services over the 6 months after initial infection.
  • A study led by Kaiser Permanente showed that COVID-19 was associated with a 4% increase in use of health care services.
  • We are recognized as one of America's leading health care providers and not-for-profit health plans.
  • Kaiser Permanente is dedicated to care innovations clinical research, health education, and the support of community health.